STOCK TITAN

[Form 4] NeueHealth, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

NeueHealth, Inc. director Robert J. Sheehy reported dispositions tied to the closing of a merger and a rollover into the buyer structure. On 10/02/2025 the reported transactions show 250,690 common shares and 15,255 common shares (separately listed) disposed, with the amount of securities beneficially owned following the transactions reported as 0 in each line. The filing explains the issuer merged into a Merger Sub and became a wholly-owned subsidiary of NH Holdings 2025, Inc., and the reporting person contributed his issuer securities into a rollover vehicle in exchange for Holdings units effective at the merger's closing.

The form clarifies the relationship: the reporting person is a director, the transactions arose from the Merger Agreement dated 12/23/2024, and the rollover occurred under a Rollover Agreement effective at the merger close.

NeueHealth, Inc. il direttore Robert J. Sheehy ha riportato disposizioni legate alla chiusura di una fusione e a un rollover nella struttura dell'acquirente. Il 10/02/2025 le transazioni riportate mostrano 250,690 azioni ordinarie e 15,255 azioni ordinarie (elencate separatamente) vendute, con la quantità di titoli beneficiari posseduti dopo le transazioni riportata come 0 in ciascuna riga. Il deposito spiega che l'emittente si è fusa in una Merger Sub e diventò una filiale interamente controllata di NH Holdings 2025, Inc., e che la persona che segnala ha contribuito i propri titoli emittenti in un veicolo di rollover in cambio di unità Holdings effettive al momento della chiusura della fusione.

La forma chiarisce la relazione: la persona che segnala è un direttore, le transazioni derivano dall'Accordo di Fusione datato 12/23/2024, e il rollover è avvenuto secondo un Accordo di rollover efficace al momento della chiusura della fusione.

NeueHealth, Inc. el director Robert J. Sheehy reportó disposiciones relacionadas con el cierre de una fusión y un rollover en la estructura del comprador. El 10/02/2025 las transacciones reportadas muestran 250,690 acciones ordinarias y 15,255 acciones ordinarias (enumeradas por separado) vendidas, con la cantidad de valores de propiedad tras las transacciones reportada como 0 en cada línea. El filing explica que el emisor se fusionó en una Merger Sub y se convirtió en una subsidiaria de propiedad absoluta de NH Holdings 2025, Inc., y la persona que reporta aportó sus valores emisores a un vehículo de rollover a cambio de unidades Holdings efectivas en el cierre de la fusión.

La forma aclara la relación: la persona que reporta es un director, las transacciones surgieron del Acuerdo de Fusión fechado el 12/23/2024, y el rollover ocurrió bajo un Acuerdo de Rollover efectivo en el cierre de la fusión.

NeueHealth, Inc. 이사 Robert J. Sheehy는 합병 종료 및 매수자 구조로의 롤오버에 연관된 처분을 보고했습니다. 10/02/2025의 보고된 거래는 250,690 일반주식과 15,255 일반주식(별도 기재) 처분을 보여주며, 각 행의 거래 후 보유 주식 수는 0로 보고됩니다. 공시는 발행인이 Merger Sub로 합병되었고 NH Holdings 2025, Inc.의 완전한 소유 자회사가 되었으며, 보고자는 합병 종결 시 롤오버 차량에 자신의 발행주를 기여해 Holdings 유닛으로 교환했다고 설명합니다.

관계는 명확히 밝혀집니다: 보고자는 이사이고 거래는 12/23/2024에 작성된 합병 계약에서 비롯되었으며, 롤오버는 합병 종결 시 발효된 롤오버 계약에 따라 이루어졌습니다.

NeueHealth, Inc. le directeur Robert J. Sheehy a signalé des dispositions liées à la clôture d'une fusion et à un rollover dans la structure de l'acheteur. Le 02/10/2025 les transactions rapportées montrent 250 690 actions ordinaires et 15 255 actions ordinaires (énumérées séparément) disposées, le montant des titres détenus bénéficiaires après les transactions étant reporté comme 0 dans chaque ligne. Le dépôt explique que l’émetteur a fusionné dans une Merger Sub et est devenu une filiale détenue en totalité par NH Holdings 2025, Inc., et que la personne déclarant a transféré ses titres émis dans un véhicule de rollover en échange d’unités Holdings effectives à la clôture de la fusion.

Le formulaire clarifie la relation : la personne déclarant est un directeur, les transactions découlent de l’Accord de Fusion daté du 23/12/2024, et le rollover s’est produit en vertu d’un Accord de rollover effectif à la clôture de la fusion.

NeueHealth, Inc. Direktor Robert J. Sheehy meldete Verfügungen im Zusammenhang mit dem Abschluss einer Fusion und einem Roll-over in die Käuferstruktur. Am 02.10.2025 zeigen die gemeldeten Transaktionen 250.690 Stammaktien und 15.255 Stammaktien (separat aufgeführt) veräußert, wobei der Betrag der nach den Transaktionen verbleibenden Eigentumswerte in jeder Zeile als 0 gemeldet wird. Die Einreichung erläutert, dass der Emittent in eine Merger Sub verschmolzen ist und eine voll beherrschte Tochter von NH Holdings 2025, Inc. geworden ist, und der meldende Person ihre Emittentenwerte in ein Roll-over-Vehikel eingebracht hat und im Austausch dafür Holdings-Einheiten wirksam zum Zeitpunkt des Abschlusses der Fusion erhalten hat.

Die Form klärt die Beziehung: Die meldende Person ist ein Direktor, die Transaktionen resultierten aus der Fusionvereinbarung datiert auf den 23.12.2024, und das Roll-over erfolgte gemäß einer Roll-over-Vereinbarung, die zum Zeitpunkt des Fusionsabschlusses wirksam wurde.

NeueHealth, Inc. مدير روبرت جي. شيهي أبلغ عن تصرفات مرتبطة بإغلاق اندماج وتحويل إلى هيكل المشتري. في 10/02/2025 تُظهر المعاملات المبلغ عنها 250,690 سهام عادية و 15,255 سهام عادية (مدرجة بشكل منفصل) مُنفذة، مع أن كمية الأوراق المالية المملوكة مفيداً بعد المعاملات المبلغ عنها كما هو مذكور في كل سطر بـ0. يوضح التسجيل أن المصدر اندمج في Merger Sub وأصبح شركة فرعية مملوكة بالكامل لـ NH Holdings 2025, Inc., وأن الشخص المبلغ قد ساهم في أوراقه المصدرية في مركبة rollover مقابل وحدات Holdings سارية عند إغلاق الاندماج.

يوضح النموذج العلاقة: أن الشخص المبلغ عنه مدير، وت Came من اتفاق الاندماج المؤرخ 23/12/2024، وحدث rollover وفق اتفاق rollover ساري المفعول عند إغلاق الاندماج.

NeueHealth, Inc. 董事 Robert J. Sheehy 报告了与收购完成及对买方结构的滚存相关的处置。于 10/02/2025 的报告交易显示 250,690 股普通股和 15,255 股普通股(分列列出)被处置,交易后报告的每行所持有的证券数量均为 0。 filing 解释称发行人并入 Merger Sub,成为 NH Holdings 2025, Inc. 的全资子公司,报告人将其发行证券注入滚存工具以换取在并购完成时生效的 Holdings 单位。

表格澄清关系:报告人为 董事,交易源自日期为 12/23/2024 的并购协议,滚存在并购完成时生效的滚存协议下进行。

Positive
  • Merger completed — the Issuer merged into Merger Sub and became a wholly‑owned subsidiary of NH Holdings 2025, Inc.
  • Rollover of equity — Reporting Person exchanged common and preferred shares for Holdings units on a one‑for‑one basis, maintaining economic exposure through the buyer
  • Director alignment — Reporting Person remained economically invested via the rollover rather than fully cashing out
Negative
  • Large disposals reported250,690 and 15,255 common shares were disposed on 10/02/2025
  • Direct beneficial ownership reported as zero following the transactions for the listed common stock lines

Insights

Director converted public shares into private‑equity rollover units at the merger close.

The transactions reflect a standard post‑acquisition rollover where public equity and preferred shares were exchanged one‑for‑one into Holdings units under a 12/23/2024 Rollover Agreement and became effective on 10/02/2025. The reporting lines show dispositions of 250,690 and 15,255 common shares with beneficial ownership reported as 0 following the transfers.

Dependencies and near‑term items to watch include the contractual terms of the rolled units (voting, liquidity, and conversion mechanics) and any subsequent filings that clarify indirect ownership or unit economics; these determine alignment and exit timing for holders in the coming months.

NeueHealth, Inc. il direttore Robert J. Sheehy ha riportato disposizioni legate alla chiusura di una fusione e a un rollover nella struttura dell'acquirente. Il 10/02/2025 le transazioni riportate mostrano 250,690 azioni ordinarie e 15,255 azioni ordinarie (elencate separatamente) vendute, con la quantità di titoli beneficiari posseduti dopo le transazioni riportata come 0 in ciascuna riga. Il deposito spiega che l'emittente si è fusa in una Merger Sub e diventò una filiale interamente controllata di NH Holdings 2025, Inc., e che la persona che segnala ha contribuito i propri titoli emittenti in un veicolo di rollover in cambio di unità Holdings effettive al momento della chiusura della fusione.

La forma chiarisce la relazione: la persona che segnala è un direttore, le transazioni derivano dall'Accordo di Fusione datato 12/23/2024, e il rollover è avvenuto secondo un Accordo di rollover efficace al momento della chiusura della fusione.

NeueHealth, Inc. el director Robert J. Sheehy reportó disposiciones relacionadas con el cierre de una fusión y un rollover en la estructura del comprador. El 10/02/2025 las transacciones reportadas muestran 250,690 acciones ordinarias y 15,255 acciones ordinarias (enumeradas por separado) vendidas, con la cantidad de valores de propiedad tras las transacciones reportada como 0 en cada línea. El filing explica que el emisor se fusionó en una Merger Sub y se convirtió en una subsidiaria de propiedad absoluta de NH Holdings 2025, Inc., y la persona que reporta aportó sus valores emisores a un vehículo de rollover a cambio de unidades Holdings efectivas en el cierre de la fusión.

La forma aclara la relación: la persona que reporta es un director, las transacciones surgieron del Acuerdo de Fusión fechado el 12/23/2024, y el rollover ocurrió bajo un Acuerdo de Rollover efectivo en el cierre de la fusión.

NeueHealth, Inc. 이사 Robert J. Sheehy는 합병 종료 및 매수자 구조로의 롤오버에 연관된 처분을 보고했습니다. 10/02/2025의 보고된 거래는 250,690 일반주식과 15,255 일반주식(별도 기재) 처분을 보여주며, 각 행의 거래 후 보유 주식 수는 0로 보고됩니다. 공시는 발행인이 Merger Sub로 합병되었고 NH Holdings 2025, Inc.의 완전한 소유 자회사가 되었으며, 보고자는 합병 종결 시 롤오버 차량에 자신의 발행주를 기여해 Holdings 유닛으로 교환했다고 설명합니다.

관계는 명확히 밝혀집니다: 보고자는 이사이고 거래는 12/23/2024에 작성된 합병 계약에서 비롯되었으며, 롤오버는 합병 종결 시 발효된 롤오버 계약에 따라 이루어졌습니다.

NeueHealth, Inc. le directeur Robert J. Sheehy a signalé des dispositions liées à la clôture d'une fusion et à un rollover dans la structure de l'acheteur. Le 02/10/2025 les transactions rapportées montrent 250 690 actions ordinaires et 15 255 actions ordinaires (énumérées séparément) disposées, le montant des titres détenus bénéficiaires après les transactions étant reporté comme 0 dans chaque ligne. Le dépôt explique que l’émetteur a fusionné dans une Merger Sub et est devenu une filiale détenue en totalité par NH Holdings 2025, Inc., et que la personne déclarant a transféré ses titres émis dans un véhicule de rollover en échange d’unités Holdings effectives à la clôture de la fusion.

Le formulaire clarifie la relation : la personne déclarant est un directeur, les transactions découlent de l’Accord de Fusion daté du 23/12/2024, et le rollover s’est produit en vertu d’un Accord de rollover effectif à la clôture de la fusion.

NeueHealth, Inc. Direktor Robert J. Sheehy meldete Verfügungen im Zusammenhang mit dem Abschluss einer Fusion und einem Roll-over in die Käuferstruktur. Am 02.10.2025 zeigen die gemeldeten Transaktionen 250.690 Stammaktien und 15.255 Stammaktien (separat aufgeführt) veräußert, wobei der Betrag der nach den Transaktionen verbleibenden Eigentumswerte in jeder Zeile als 0 gemeldet wird. Die Einreichung erläutert, dass der Emittent in eine Merger Sub verschmolzen ist und eine voll beherrschte Tochter von NH Holdings 2025, Inc. geworden ist, und der meldende Person ihre Emittentenwerte in ein Roll-over-Vehikel eingebracht hat und im Austausch dafür Holdings-Einheiten wirksam zum Zeitpunkt des Abschlusses der Fusion erhalten hat.

Die Form klärt die Beziehung: Die meldende Person ist ein Direktor, die Transaktionen resultierten aus der Fusionvereinbarung datiert auf den 23.12.2024, und das Roll-over erfolgte gemäß einer Roll-over-Vereinbarung, die zum Zeitpunkt des Fusionsabschlusses wirksam wurde.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
X
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Sheehy Robert J

(Last) (First) (Middle)
C/O NEUEHEALTH, INC.
9250 NW 36TH ST SUITE 420

(Street)
DORAL FL 33178

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
NeueHealth, Inc. [ NEUE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/02/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/02/2025 D(1) 250,690 D (2) 0 I By Robert J. Sheehy Revocable Trust
Common Stock 10/02/2025 D(1) 15,255 D (2) 0 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. On October 2, 2025, NH Holdings 2025, Inc. ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and NH Holdings Acquisition 2025, Inc., a wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of December 23, 2024 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). Parent and Merger Sub are indirectly controlled by private investment funds affiliated with New Enterprise Associates, Inc.
2. Pursuant to the Rollover Agreement, dated as of December 23, 2024 (the "Rollover Agreement"), entered into by and among NH Holdings 2025 SPV, L.P. ("Holdings"), NH Holdings 2025, Inc., NH Holdings Acquisition 2025, Inc. and the Reporting Person, the Reporting Person contributed its shares of Issuer common stock, Series A Convertible Perpetual Preferred Stock ("Series A Preferred Stock") and Series B Convertible Perpetual Preferred Stock ("Series B Preferred Stock") to Holdings in exchange for Holdings common units, series A preferred units and series B preferred units on a one for one basis in accordance with the Rollover Agreement, and effective as of the effective time of the Merger (the "Effective Time").
Remarks:
/s/ Eric Halverson for Robert J. Sheehy, Attorney-in-Fact 10/06/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Robert J. Sheehy report on Form 4 for NEUE?

The Form 4 shows dispositions of 250,690 and 15,255 common shares on 10/02/2025, with those holdings contributed into a rollover vehicle.

Why were the shares disposed according to the filing?

The filing states the disposals occurred because the issuer completed a merger and the reporting person contributed securities to the buyer’s rollover vehicle under a Rollover Agreement.

Did the filing indicate the merger closed?

Yes. The filing explains the Issuer merged into Merger Sub and became a wholly‑owned subsidiary of NH Holdings 2025, Inc., effective 10/02/2025.

Does Robert J. Sheehy still have economic exposure after the transactions?

According to the Explanation, he received Holdings common units and preferred units in exchange for his Issuer securities on a one‑for‑one basis, indicating continued economic exposure via the buyer structure.

What agreements govern these transactions?

The transactions reference an Agreement and Plan of Merger dated 12/23/2024 and a Rollover Agreement dated 12/23/2024.

When was the Form 4 signed and filed?

The signature block shows an attorney‑in‑fact signed on 10/06/2025.
NeueHealth Inc

NYSE:NEUE

NEUE Rankings

NEUE Latest News

NEUE Latest SEC Filings

NEUE Stock Data

60.94M
7.28M
9.45%
58.37%
0.14%
Healthcare Plans
Hospital & Medical Service Plans
Link
United States
DORAL